Rosetta Inks Deal for Rockefeller microRNAs
Rosetta Genomics and Rockefeller University said this week that they have signed an agreement under which Rosetta will add about 180 of the university's proprietary microRNAs to its miRNA database.
Under the deal, Rosetta said it will be able to use the miRNAs to potentially advance multiple research development programs targeting new microRNA-based diagnostic tools for a variety of diseases.
Additional terms of the arrangement were not disclosed.
Galapagos to Buy DPI's Drug-Discovery Service Arm for $5.4M
Galapagos will acquire the entire drug-discovery service operation of Discovery Partners International for €4.25 million ($5.4 million) in cash, the companies said this week.
Under the terms of the agreement, Galapagos will acquire all of the outstanding capital stock or equity interests of DPI subsidiaries Discovery Partners International, ChemRx Advanced Technologies, Xenometrix, and Discovery Partners International, as well as certain contracts connected with the transaction.
Galapagos, headquartered in Mechelen, Belgium, will inherit DPI's four service sites located in San Diego and South San Francisco, Calif., Basel, Switzerland, and Heidelberg, Germany; as well as DPI's Japanese sales office in Tokyo.
The companies anticipate layoffs of general and administrative staff in the San Diego facility, but expect all four of the DPI services locations to remain fully operational. There are approximately 100 people employed at the acquired sites, which will bring the total Galapagos headcount to more than 320, the companies said.
Galapagos also said that it will merge the service sites into BioFocus, its drug-discovery services division, and, as a result, will change the name of the division to BioFocus DPI.
Galapagos anticipates that DPI operations will contribute more than €8 million in external revenues to BioFocus DPI for the six months remaining in 2006. Major 2006 customers for these operations include Actelion, Allergan, Biovitrum, GlaxoSmithKline, Mitsubishi Pharma, the US National Institutes of Health, Novartis, and Ono, the companies said.